This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs will be responsible for launching these products in India and emerging markets.
The old model of looking at performance in the first six months of product launch isn’t relevant. Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences. What is the definition of a successful pharmaproduct launch?
Learn valuable marketing lessons for B2B pharmacompanies by examining successful strategies used in the B2C prescription market, including over-the-counter (OTC) products and interactions with healthcare professionals (HCPs).
said: “As a company that aspires to being a pioneer of modern, high quality and healthy living, we will expand our healthcare activities both in Turkey and international markets with innovative products and a wide product portfolio in different treatment areas. The post Eczac?ba??
Online health seekers are a valuable opportunity for pharma to bridge the trust gap. The last two weeks I was asked to look at the website metrics for a pharmacompany’s top product sites. You can’t shortcuts when building a product website, you need to follow the map.
In the pharma sector, running a PCD PharmaCompany in India guarantees good returns. What is a PCD PharmaCompany? In this model, PCD pharmacompanies are those who give products to the established companies and give monopoly rights to a region. Are you a small entrepreneur in the niche?
Those, who don’t mind taking a risk in the business must reap the opportunity by launching a pharmacompany. Before you make up your mind about launching the pharma business, you should know about the investment requirements. There are various prerequisites and legal compliances before launching a pharmacompany.
Incannex Healthcare has collaborated with New Jersey-based pharmacompany Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. It will also be potentially used for wider commercial use or supply as a cGMP pharmaceutical-grade product.
But now, pharmacompanies have an even more powerful tool to start those conversations and turn them into prescriptions: telemedicine. Drug ads have long tried to influence patients’ medical choices, directing them to “ask your doctor” if a marketed medication is right for them. Read the rest…
We know that the PCD Pharma Franchise business is lucrative and profitable. But do we know which PCD products should we pick so that the maximum profitability is ensured? This blog is an attempt to clarify the concepts about choosing the best products. First, choose the right company. Legally identified products.
Indian pharma sees immense value in US FDA’s insistence for aluminum content and labelling recommendations for the Small Volume Parenterals Drug Products and Pharmacy Bulk Packages. Pharmacompanies in the country have increasingly made a shift to nutritional based prescription and over the counter products.
The findings explore the long-term trends underway in the global nutraceutical industry, with consumers predicted to increase spending on natural products and sustainable formulations that can offer ‘preventative or proactive’ health benefits. The report was made by CPhI’s.
Family businesses across industries including the life sciences sector contribute significantly to the global economy – they represent about half of the world gross domestic product and global employment. The post The benefits of being a family-run pharmacompany appeared first on.
The future of reaching HCPS is both on and off-line depending on the product, health condition, and specialty. Zoom Rx recently polled HCPs and found 78% of physicians want to maintain some contact with pharma reps. 3hree: DMD – DMD can precisely target HCPs using your product website and email.
The new patent comes at a key time for the pharma industry with more than ten advanced therapies anticipated to be approved in the next year as pharmacompanies continue to struggle with how.
Further, 62% of HCPs said that the most significant area where pharma representatives can add value is, by understanding the needs of HCPs and sharing only relevant content with them to make the interactions more insightful. At the same time, marketing emails are among the top 5 channels used by pharmacompanies to engage HCPs.
Continuous manufacturing produces a drug product from start to finish through a nonstop, integrated assembly. In contrast, most of the pharmaceutical industry currently uses batch manufacturing, which involves producing a finished drug product through multiple distinct steps in series. I’m talking about continuous manufacturing.
With only 2% to 3% of the current level of available data leveraged, there is substantial room for growth, and Youssef says pharma could help make a significant impact. The post The largest pharmacompany in Europe calls for interoperability appeared first on.
Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies. In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharmacompanies.
86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. HCPs don’t necessarily want pharma trying to sell products via social media. Doximity was flagged for having anti-vaccine information.
Further, 62% of HCPs said that the most significant area where pharma representatives can add value is, by understanding the needs of HCPs and sharing only relevant content with them to make the interactions more insightful. At the same time, marketing emails are among the top 5 channels used by pharmacompanies to engage HCPs.
Let’s be clear about pharmaproduct websites. In short, online health seekers aren’t finding compelling reasons to ask for your product on your website. The potential to increase compliance and adherence is unlimited with EHR integration by pharmacompanies.
Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharmacompanies’ content, but is it a good idea? Pharmacompanies have policies that heavily restrict their use of social media and limit their ability to benefit from the wealth of data that could accompany it.
SUS provides full, free and universal access to healthcare for the country's entire population (215 million), which spends around 10% of its gross domestic product (GDP) on healthcare. Only a limited number of international pharmacompanies, however, operate manufacturing sites in the country.
A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? The pandemic also saw a reduction in the overall development cycle of a product, which has been growing in recent years. In 2020, the development cycle averaged 7.14
She continues: “Whether a vendor has a cloud-based registry, system, or database, it’s crucial that pharmaceutical companies who pre-tag for RFID systems use accepted, recognized global standards to encode drug data so products can be read by any system, just like the GS1 barcodes that are on every pharmaceutical product today.”
Just 13% of people trust the pharmacompanies they interact with. If pharma is going to leap to a new era of marketing, they have to get to know their audiences. Drug companies can’t afford to supply prescription drugs; they need to get to know what their audience needs and wants to stay on branded products.
Just look at any pharmaproduct website that is nothing but a sales brochure in a majority of cases. ROI drives pharmacompanies. In the past, pharmaproduct websites had a huge effect on whether a patient asks for an Rx. 4our: Make your website about “wellness,” not just about your product.
Some patients love the brand of prescription drugs they take because simply “they work” Pharmacompanies do study brand names, but that’s only about the overall branding of the product. Depending on your brand strategy, this could mean efficacy, cost or a better quality of life.
Earning trust is not done through one act or with one product; it’s done through a consistent emphasis on transparency. Of course, the media is jumping on the WHO’s recommendation to eliminate Gilead’s product from COVID treatments.
At 99% of pharmacompanies, that's a huge no-no. On top of this, “the company also revealed that the Federal Trade Commission and the Securities and Exchange Commission had opened two new, separate investigations into the troubled biotech. At 99% of pharmacompanies, that’s a huge no-no.
Jupiter Neurosciences, a clinical-stage pharmacompany specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00
This is one area where pharmacompanies can restore trust and excel. . Right now, people don’t come to pharma websites unless DTC drives them for a specific product. Pharmacompanies have access to some of the best physicians in the country, and they are underutilized when helping patients understand health issues.
Pharmaceutical companies are under increasing pressure to ensure that essential healthcare products are accessible to all, regardless of socioeconomic status or location.
This is partly due to the differing business models used by pharmacompanies and digital therapeutic developers. Lastly, wellness products can address symptoms, but do not manage and treat them, he adds. But creating a combined product is tricky from a regulatory perspective, says Sørensen.
During the pandemic, DTC commercials have pretty much remained the same as having product websites. Sure your product may lower A1C, but is that alone enough to get someone to schedule a telehealth visit with their doctor? DTC needs to reach out to audiences to motivate them to ask for a product.
The politics of working with a major pharmacompany can be a difficult challenge. Just when you think you have broken through, pharma marketing, people rotate, leave, or get promoted, and the process is pushed back three or four steps. The other change that agencies need to push is the idea that product websites are alive.
Yet the company moved ahead because the CEO was under pressure to justify the money the company had invested in the drug. Aduhelm is being rejected by most health plans and is a failed product. In trying to save the product, Biogen’s reputation was trashed by FDA advisors, HCPs, and the healthcare media.
The German bio pharmacompany on Tuesday announced ambitious pipeline plans that include starting 10 new Phase II and III trials over the next 12 to 18 months.
New digital products always rely on early adopters to create a community and improve the product. It is this passion and fundamental need for change that suggests digital products can have a higher success rate when supporting rare disease communities. Create a human experience of care. A work of passion. About Thomas Michalak.
Executives at Pfizer, Merck, and Novartis are looking for promising drugs to add to their pipelines and replenish sales as top-selling products lose patent protection in the coming years. Meanwhile, AbbVie is lifting a self-imposed $2 billion limit on the size of deals it would do to add more products.
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharmacompany BioNTech has said it will start manufacturing vaccines in Africa.
It is evident that HCPs are extremely time constraint and prefer to engage with pharma organizations on their terms regarding channel, content, and type of devices. In addition, 62% of HCPs are overwhelmed by product-related promotional content pushed by pharmacompanies on the various digital channels.
Last week I had a chance to review a creative brief submitted to an agency to launch a new product. 1ne: Pharmacompanies are forcing out older, experienced employees. 2wo: Talented marketing people don’t want to work in pharma because of the culture. It was one of the worst briefs I have ever read. Pure fantasy.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content